Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.64 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.58 |
| ▸ | PDE4A | P27815 | 4/20 | 0.58 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.58 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.50 |
| ▸ | STS | P08842 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL223791 | 0.87 | GPR119 (0.64) | GPR119PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL15375545 | 0.85 | PDE4B (0.48) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL31583988 | 0.83 | PDE4B (0.64) | GPR119PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL2277132 | 0.83 | PDE4B (0.64) | GPR119PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL6486054 | 0.82 | PDE4B (0.69) | GPR119PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL225375 | 0.82 | GPR119 (0.91) | GPR119ALK | |
| SCHEMBL19839235 | 0.81 | PDE4B (0.64) | GPR119PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL21886989 | 0.81 | GPR119 (0.56) | GPR119PDE4BALK | |
| SCHEMBL1560104 | 0.80 | PDE4B (0.45) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL3605978 | 0.80 | GPR119 (0.69) | GPR119ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303276-B1 | FUMARATE SALT OF 4-(3-CHLORO-2-FLUOROANILINO)-7-METHOXY-6-{[1-(N-METHYLCARBAMOYLMETHYL)PIPERIDIN-4-YL]OXY}QUINAZOLINE | ASTRAZENECA AB (SE) | 2013-11-13 | — | — | EP | disclosed |
| EP-2303276-B1 | FUMARATE SALT OF 4-(3-CHLORO-2-FLUOROANILINO)-7-METHOXY-6-{[1-(N-METHYLCARBAMOYLMETHYL)PIPERIDIN-4-YL]OXY}QUINAZOLINE | ASTRAZENECA AB (SE) | 2013-11-13 | — | — | EP | disclosed |
| US-8450482-B2 | Process for the preparation of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-([1-(N-methylcarbamoymethyl)piperidin-4-yl]oxy)quinazoline | ASTRAZENECA AB (SE) | 2013-05-28 | — | — | US | disclosed |
| US-8450482-B2 | Process for the preparation of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-([1-(N-methylcarbamoymethyl)piperidin-4-yl]oxy)quinazoline | ASTRAZENECA AB (SE) | 2013-05-28 | — | — | US | disclosed |
| US-8450482-B2 | Process for the preparation of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-([1-(N-methylcarbamoymethyl)piperidin-4-yl]oxy)quinazoline | ASTRAZENECA AB (SE) | 2013-05-28 | — | — | US | disclosed |
| US-8404839-B2 | Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy} quinazoline difumarate Form A | ASTRAZENECA AB (GB) | 2013-03-26 | — | — | US | disclosed |
| US-8404839-B2 | Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy} quinazoline difumarate Form A | ASTRAZENECA AB (GB) | 2013-03-26 | — | — | US | disclosed |
| US-8404839-B2 | Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy} quinazoline difumarate Form A | ASTRAZENECA AB (GB) | 2013-03-26 | — | — | US | disclosed |
| US-20120108814-A1 | PROCESS 738 | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| US-20120108814-A1 | PROCESS 738 | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| WO-2010122340-A2 | PROCESS 738 | ASTRAZENECA AB (SE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010061208-A2 | THERAPEUTIC TREATMENT 555 | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010061208-A2 | THERAPEUTIC TREATMENT 555 | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | WO | disclosed |
| WO-2009138781-A1 | FUMARATE SALT OF 4- (3-CHLORO-2-FLUOROANILINO) -7-METHOXY-6- { [1- (N-METHYLCARBAMOYLMETHYL) PIPERIDIN- 4-YL] OXY}QUINAZOLINE | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009138781-A1 | FUMARATE SALT OF 4- (3-CHLORO-2-FLUOROANILINO) -7-METHOXY-6- { [1- (N-METHYLCARBAMOYLMETHYL) PIPERIDIN- 4-YL] OXY}QUINAZOLINE | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
| US-20090286982-A1 | NOVEL SALT-554 | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | US | disclosed |
| US-20090286982-A1 | NOVEL SALT-554 | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | US | disclosed |
| US-20090286982-A1 | NOVEL SALT-554 | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | US | disclosed |
| WO-2009138779-A1 | COMBINATION COMPRISING 4- (3-CHLORO-2-FLUOROANILINO) -7-METH0XY-6- { [1- (N-METHYLCARBAMOYLMETHYL) PIPERIDIN- 4-YL] OXYJQUINAZOLINE | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009138779-A1 | COMBINATION COMPRISING 4- (3-CHLORO-2-FLUOROANILINO) -7-METH0XY-6- { [1- (N-METHYLCARBAMOYLMETHYL) PIPERIDIN- 4-YL] OXYJQUINAZOLINE | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286982-A1 | NOVEL SALT-554 | KRAS, NISCH, WASHC4 | GPR119 4491/4885PDE4B 1624/4885PDE4D 2379/4885 |
| US-20120108814-A1 | PROCESS 738 | CYP2C8, CYP4F8, UGT1A8 | GPR119 4796/4885PDE4B 1770/4885PDE4D 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.